Bipolar II Disorder

Article written and reviewed by Dr Luca Moretti

Bipolar II disorder is a mood disorder characterized in the DSM-5-TR by the lifetime presence of at least one hypomanic episode and at least one major depressive episode, with no previous manic episode. In ICD-11, the corresponding category is bipolar type II disorder, code 6A61, likewise defined by hypomanic and depressive episodes in the absence of a history of mania.

Type II is not simply a “mild” form of bipolar I disorder. Hypomania is by definition less severely impairing than mania, but the overall course may be highly disabling because many patients spend a substantial proportion of time in depression or with residual symptoms. Functional disability and suicide risk may be considerable, and contemporary studies do not support the idea that bipolar II disorder is clinically benign.

Hypomania consists of a distinct period of elevated, expansive or irritable mood associated with increased activity or energy and other activation symptoms. The change is clearly different from usual functioning and observable by other people, but is not severe enough to cause marked social or occupational impairment, require hospitalization or produce psychotic symptoms. If psychosis or impairment of manic severity occurs, the episode is no longer hypomanic.

The World Mental Health Survey Initiative estimated the lifetime prevalence of bipolar II disorder at approximately 0.4%, but epidemiological values depend strongly on the ability of diagnostic instruments to identify hypomanic episodes that are often not perceived as pathological. Patients tend to seek care during depression, while they may describe hypomania as a period of greater energy, creativity or efficiency.

Onset often occurs between adolescence and young adulthood. A prolonged interval between the first symptoms and diagnosis is common, particularly when hypomanic phases are brief, nondisruptive or never systematically reconstructed. Many patients initially receive a diagnosis of major depressive disorder until a reliable history of hypomania emerges.

The course is predominantly recurrent. Depressive and hypomanic episodes and periods of remission may alternate with highly variable frequency. In many patients the depressive burden exceeds the hypomanic burden; anxiety comorbidity, substance use disorders, migraine, eating disorders and other conditions may increase clinical complexity.

Etiology, Pathogenesis and Pathophysiology

As in bipolar I disorder, no single cause of bipolar II disorder has been identified. Available data support a multifactorial and polygenic model involving interactions among genetic susceptibility, brain development, circadian regulation, stress, sleep and environmental factors. The clinical distinction between type I and type II does not correspond to complete biological separation.

Bipolar disorder shows strong familial aggregation. Having an affected first degree relative increases risk but does not inevitably determine illness. Genomic studies show substantial sharing of risk variants between bipolar I and II disorder, together with quantitative differences and genetic overlap with major depression and schizophrenia.

Large GWAS have confirmed that risk is distributed across numerous loci. Recent analyses in very large multiethnic samples identified hundreds of associations and showed differences in genetic correlations between subtypes and ascertainment methods. These findings are relevant to research but do not allow an individual patient with unipolar depression to be distinguished from one with bipolar II disorder using a genetic test.

Early adverse events, psychosocial stress and sleep disturbances are associated with episode risk and recurrence. Their role is probabilistic. In bipolar II disorder, sleep deprivation may precede periods of activation, while persistent insomnia may accompany or precede depression; the direction of the association may therefore vary over time.

Neurobiology is studied mainly within the bipolar spectrum as a whole. Group level structural and functional alterations involve prefrontal, limbic and striatal networks regulating reward, salience, cognitive control and emotional response. The large overlap with healthy controls and other disorders makes these findings unsuitable for individual diagnosis.

Modulation of dopaminergic, glutamatergic, GABAergic and serotonergic systems probably contributes to changes in energy, motivation and mood. The efficacy of lithium, atypical antipsychotics, lamotrigine and other treatments suggests involvement of multiple neurotransmitter and intracellular pathways rather than a single neurotransmitter “deficiency” or “excess”.

Synaptic plasticity and intracellular signaling systems are additional areas of interest. Lithium and anticonvulsant medications modify the inositol cascade, intracellular kinases, gene expression and synaptic function; antipsychotics modulate dopaminergic and serotonergic receptors with broader network effects. The pathophysiology of the illness cannot be inferred from a single pharmacological mechanism.

Studies of inflammation, oxidative stress and mitochondrial function have identified average abnormalities in subgroups of patients. These findings may be influenced by illness state, obesity, smoking, medications and comorbidities. No inflammatory or metabolic marker is validated to distinguish type II disorder from major depression or type I disorder in clinical practice.

Circadian regulation is particularly important because the disorder manifests through episodic changes in sleep, energy and activity. Irregularities in social and biological rhythms may facilitate destabilization in vulnerable individuals, while interventions that stabilize sleep and routines are a useful component of relapse prevention.

Psychologically, hypomanic periods may be reinforced by perceived increases in productivity and gratification, reducing the likelihood that the patient will regard them as pathological. During depression, rumination, pessimism, anhedonia and behavioral withdrawal may predominate. Understanding these dynamics is relevant to psychoeducation and psychotherapy.

Mixed features show that activation and depression are not mutually exclusive processes. A depressive episode may contain subthreshold hypomanic symptoms, which can increase agitation, impulsivity and therapeutic complexity. Mixed features should be documented without automatically treating them as evidence of a full hypomanic episode.

In summary, bipolar II disorder arises from a distributed biological vulnerability interacting with environmental and circadian factors. The absence of diagnostic biomarkers means that distinction from unipolar depression depends on longitudinal reconstruction of hypomania.

Clinical Manifestations

The most common presentation to clinical attention is a major depressive episode. The patient may report depressed mood, loss of interest, fatigue, changes in sleep and appetite, cognitive difficulties, guilt and thoughts of death. These symptoms alone do not distinguish bipolar II depression from unipolar major depression.

For this reason, the history must actively explore previous periods of activation. It is not enough to ask whether the patient has ever been “euphoric”, because hypomania may be predominantly irritable or experienced as a period of wellbeing. It is more useful to reconstruct distinct periods with less need for sleep, greater energy, increased talkativeness, racing thoughts, greater sociability, increased libido or an unusual increase in activity and projects.

During a hypomanic episode, mood may be elevated, expansive or irritable. The patient may feel particularly confident, bright or productive, but the change must be unequivocal relative to baseline and not simply a return to normal energy after depression.

Reduced sleep is an important clinical feature. Hypomania typically involves a reduced need for sleep, with only a few hours of rest and no resulting fatigue. Simple insomnia with daytime tiredness does not have the same phenomenological meaning.

Increased self esteem, talkativeness, racing thoughts, distractibility, increased goal directed activity and greater involvement in pleasurable or risky activities may be present. Intensity must not, however, reach the level of impairment characteristic of mania.

An essential clinical criterion is that the change be observable by others. Family members, partners and colleagues may recall periods when the patient talked much more, slept less, was more sociable or enterprising. Collateral information is especially useful when the patient does not regard these periods as problematic.

Hypomania does not cause the marked social or occupational impairment characteristic of mania, does not require hospitalization because of its severity and does not include psychotic symptoms. If these elements occur, the episode should be classified as manic and the diagnosis becomes bipolar I disorder.

Depression often occupies a larger part of the course. It may be severe, recurrent, associated with psychotic symptoms and with substantial suicide risk. Psychosis during a depressive episode does not make the disorder bipolar I; it is the presence of mania, not the severity of depression, that formally distinguishes the two subtypes.

Mixed features are clinically important. During depression, increased energy, talkativeness, racing thoughts or other symptoms of the opposite polarity may emerge without a separate hypomanic episode. These presentations may be associated with greater agitation and require particular caution in treatment selection.

Assessment should reconstruct age at onset, number and duration of episodes, remissions, seasonality, postpartum phases, treatment response and previous mood switches. Antidepressant use may reveal activation symptoms; to count as a hypomanic episode for diagnostic purposes, the presentation must meet syndromic criteria and persist beyond the simple physiological effect of treatment.

Comorbidity with anxiety disorders, substance use, ADHD, eating disorders and personality disorders is common. These conditions may modify presentation and increase impulsivity, instability and suicide risk, making a multidimensional diagnostic formulation necessary.

Suicidal behavior should be assessed at every clinically significant visit. Bipolar II disorder may involve suicide attempts and, in some analyses, suicide mortality comparable with that of type I disorder. The perception of a “mild form” may therefore be dangerously misleading.

On mental status examination, hypomania may show increased energy, faster speech, lively affect, distractibility and increased self esteem, but without severe disorganization. During depression, reduced reactivity, psychomotor slowing or agitation, negative thinking and possible thoughts of death predominate.

Functioning should be assessed across the entire course. Even when hypomania appears subjectively advantageous, repeated cycling, depression and residual symptoms may impair relationships, work and financial stability. The clinical goal is not to eliminate normal mood variability but to prevent pathological episodes and restore stable functioning.

Assessment and Diagnosis

The diagnosis of bipolar II disorder is clinical and requires documentation of both polarities specified by the classification. There is no laboratory or neuroimaging test that distinguishes type II disorder from major depression. The most frequent error is to correctly identify depression but fail to recognize previous hypomania.

The diagnostic sequence includes safety assessment, confirmation of a major depressive episode when present, systematic search for hypomanic episodes, exclusion of mania, reconstruction of the temporal relationship with substances or medical conditions, and differential diagnosis with other disorders characterized by affective instability.

Essential DSM-5-TR criteria for a hypomanic episode

• A distinct period of abnormally and persistently elevated, expansive or irritable mood and abnormally and persistently increased activity or energy lasting at least four consecutive days, present for most of the day nearly every day.
• During the period, at least three symptoms are present among increased self esteem or grandiosity, reduced need for sleep, increased talkativeness or pressure to keep talking, flight of ideas or racing thoughts, distractibility, increased goal directed activity or psychomotor agitation, and involvement in activities with a potential for harmful consequences; at least four symptoms are required if the mood is only irritable.
• The episode is associated with an unequivocal change in functioning that is uncharacteristic of the individual when asymptomatic, and the disturbance in mood and functioning is observable by other people.
• The episode is not severe enough to cause marked social or occupational impairment or require hospitalization; if psychotic features are present, the episode is by definition manic.
• The episode is not attributable to the physiological effects of a substance.

DSM-5-TR requirements for bipolar II disorder

• Criteria have been met over the lifetime for at least one hypomanic episode and at least one major depressive episode.
• There has never been a manic episode.
• The episodes are not better explained by schizophrenia spectrum disorders or other psychotic disorders.
• The alternation between depressive and hypomanic periods causes clinically significant distress or impairment in social, occupational or other important areas of functioning.

ICD-11 uses category 6A61 and retains the requirement for depressive and hypomanic episodes without a history of mania. The duration and requirements for hypomania in ICD-11 should not automatically be replaced by DSM thresholds; clinicians should consistently apply the chosen classification system.

The main comparison is with major depressive disorder. No feature of the current depression is pathognomonic for bipolarity. Early onset, high recurrence, a family history of bipolar disorder, depression with atypical or mixed features, and antidepressant associated activation increase suspicion but do not replace a documented hypomanic episode.

Questionnaires such as the HCL-32, Mood Disorder Questionnaire and Bipolar Spectrum Diagnostic Scale may support history taking in selected individuals. A positive result does not establish a diagnosis; a negative result does not exclude the disorder. Their greatest value is to prompt a more detailed clinical interview.

Borderline personality disorder is a common differential diagnosis. Emotional instability in borderline personality disorder is typically reactive to interpersonal events and associated with a pervasive pattern of identity and relational difficulties, whereas hypomania is a distinct episode with changes in energy and activity. The two conditions may nevertheless coexist.

ADHD may cause distractibility, impulsivity and increased activity, but has a persistent, nonepisodic neurodevelopmental course. Anxiety may cause insomnia and restlessness without the characteristic increase in energy and goal directed behavior of hypomania.

Stimulant substances, corticosteroids and other exposures may induce hypomanic or manic symptoms. Onset, dose, duration and any persistence after discontinuation should be reconstructed. If symptoms are better explained by a direct physiological effect, the diagnosis belongs to the substance or medication induced categories.

Blood tests are directed toward differential diagnosis and treatment safety. TSH, complete blood count, renal and liver function, electrolytes, metabolic parameters and other tests are requested according to the presentation and planned medications. There is no diagnostic blood value for bipolar II disorder.

Neuroimaging and EEG are reserved for atypical presentations, neurological signs, seizures, trauma, cognitive decline or other features suggesting an organic cause. Research neuroimaging studies have not produced an individual clinical test.

Once diagnosis is established, the current or most recent episode, severity, remission, mixed features, anxiety, seasonal pattern and, when applicable, rapid cycling should be specified. The rapid cycling specifier requires at least four mood episodes within twelve months and should not be confused with hourly or daily fluctuations.

Assessment is completed by evaluating suicide risk, comorbidities, physical health, functioning, social support, medication history and the patient’s goals. This information is essential for selecting an appropriate treatment strategy.

Treatment and Prognosis

Treatment should separately address acute depression, clinically problematic hypomania and relapse prevention. Evidence specific to type II disorder is less abundant than for type I; many recommendations derive from studies including both subtypes, although literature specifically focused on bipolar II disorder has increased in recent years.

In bipolar II depression, CANMAT/ISBD identifies quetiapine as a first line treatment based on available evidence. Lithium and lamotrigine are important subsequent or maintenance options; choice depends on severity, predominant polarity, previous responses and safety profile.

Some antidepressants, particularly sertraline or venlafaxine, have been considered by CANMAT/ISBD as second line options in selected patients with nonmixed bipolar II depression. This position does not amount to a general recommendation: activation risk, history of switching and the presence of mixed features must be assessed carefully.

VA/DoD guidelines for bipolar depression, applicable to bipolar I and II disorder, recommend quetiapine and include cariprazine, lumateperone, lurasidone and olanzapine among evidence supported monotherapies. Regulatory availability of individual indications varies between countries.

Electroconvulsive therapy may be indicated for severe, psychotic, catatonic, highly suicidal or treatment resistant depression, particularly when a rapid response is needed. ECT is an effective somatic therapy and is not reserved exclusively for bipolar I disorder.

Treatment of hypomania depends on intensity, consequences and risk of progression. Exposure to substances or treatments that promote activation should be stopped or corrected when appropriate. Mood stabilizers and antipsychotics used in mania may be considered in clinically significant presentations, but the specific evidence base for hypomania in type II disorder is more limited.

During maintenance, quetiapine, lithium and lamotrigine are among the best supported options for bipolar II disorder. The pattern of previous episodes is important: lamotrigine is particularly oriented toward prevention of depression, while lithium has broad mood stabilizing effects and substantial relevance to suicide prevention.

Pharmacological treatment should be accompanied by specific monitoring. Lithium requires serum levels and monitoring of renal and thyroid function; lamotrigine must be titrated slowly to reduce the risk of severe skin reactions; antipsychotics require monitoring of weight and metabolic parameters.

Psychoeducation helps patients recognize hypomania and depressive prodromes, improve adherence and stabilize daily rhythms. It is particularly useful in type II disorder because patients may not perceive hypomanic phases as pathological and may wish to regain the subjective increase in energy associated with them.

Cognitive behavioral therapy, family focused therapy, and interpersonal and social rhythm therapy may be integrated with pharmacotherapy. Psychotherapies are especially useful for treating depression, managing comorbidities and preventing relapses; they do not replace pharmacological treatment when the presentation requires biological stabilization.

Regularizing sleep is a concrete therapeutic goal. Highly irregular schedules, nights without sleep, destabilizing shifts and stimulant use should be discussed. In patients with a seasonal pattern or particular circadian sensitivity, chronobiological interventions require supervision because of the possible risk of activation.

Alcohol and substances may worsen depression, impulsivity and instability. Treatment of substance use comorbidities should be integrated into bipolar disorder care rather than postponed until complete mood stabilization.

Medication related reproductive risk should be considered systematically. Valproate carries important teratogenic and neurodevelopmental risks and is subject to strict restrictions in people with reproductive potential. Lithium and other medications also require individualized assessment during pregnancy and the puerperium.

Prognosis is variable and depends primarily on depressive burden, relapse frequency, comorbidities, suicidal behavior and adherence. Many patients achieve good functioning with continuous treatment, but recurrent depressive episodes may cause substantial disability.

Delayed diagnosis may prolong exposure to suboptimal treatments and the period during which illness is inadequately stabilized. Accurate recognition of hypomania can therefore substantially change treatment strategy, especially in patients initially considered to have unipolar depression.

Follow up should aim not only for symptom remission but also for functional recovery, suicide prevention, protection of metabolic and cardiovascular health, and reduction of the social consequences of episodes.

Complications

Suicidal behavior is one of the most important complications. Risk is particularly related to depressive episodes and mixed features. Recent reviews indicate that the risk of death by suicide in bipolar II disorder may be similar to that observed in type I, which is why the diagnosis should not be considered prognostically mild.

Recurrent depressive episodes may lead to job loss, interruption of education, reduced productivity and isolation. Functioning may remain impaired even after syndromic remission because of cognitive symptoms, anxiety, insomnia or residual fatigue.

Hypomania may cause impulsive decisions, spending, conflict, risky sexual behavior and substance use without reaching the severity of mania. Lack of insight may delay intervention because the patient attributes the behavior to a period of wellbeing.

The occurrence of a true manic episode during follow up changes the diagnosis to bipolar I disorder. This is not a biologically distinct “complication”, but a longitudinal reclassification when the clinical history meets new criteria.

Anxiety comorbidities may amplify depression, insomnia and avoidance behavior. Substance use disorders increase impulsivity, instability and suicide risk and may interfere with pharmacotherapy.

Treatment may cause metabolic, neurological, endocrine or renal complications depending on the medication. Risk does not justify withholding treatment but requires informed selection and structured monitoring.

In patients treated with antidepressants, mood activation, hypomania or, more rarely, acceleration of the course may occur. Risk varies between medications and patients and should be interpreted in the context of individual history, avoiding both indiscriminate use and the assumption that every antidepressant inevitably causes switching.

Persistence of subthreshold symptoms and closely spaced relapses may promote a functionally chronic course. Prevention requires maintenance treatment, early recognition of prodromes and management of comorbidities.

Obesity, diabetes and cardiovascular disease are more common in populations with bipolar disorder and may be worsened by some antipsychotics. Metabolic monitoring, physical activity, smoking cessation and access to general preventive care are integral parts of treatment.

Pregnancy and especially the postpartum period may be periods of destabilization. Treatment planning should balance relapse risk with fetal or neonatal safety and avoid unsupervised discontinuation.

Relational impairment may result from both depression and periods of irritability, impulsivity and increased activity. Involving the family in psychoeducation, with the patient’s consent, may facilitate early recognition of mood changes.

Optimal management of bipolar II disorder therefore requires a longitudinal perspective: the main source of morbidity is not the individual hypomanic episode but the interaction over time among recurrent depression, instability, suicide risk, comorbidities and treatment consequences.

Bibliography
1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR). American Psychiatric Association Publishing; 2022.
2. World Health Organization. Clinical descriptions and diagnostic requirements for ICD-11 mental, behavioural and neurodevelopmental disorders. World Health Organization; 2024.
3. Berk M et al. Bipolar II disorder: a state-of-the-art review. World Psychiatry. 24(2), 2025: 175-189.
4. Yatham LN et al. Canadian Network for Mood and Anxiety Treatments and International Society for Bipolar Disorders 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disorders. 20(2), 2018: 97-170.
5. Keramatian K et al. The CANMAT and ISBD Guidelines for the Treatment of Bipolar Disorder: Summary and a 2023 Update of Evidence. Focus. 21(4), 2023: 344-353.
6. Department of Veterans Affairs et al. VA/DoD Clinical Practice Guideline for the Management of Bipolar Disorder. Version 2.0. Department of Veterans Affairs and Department of Defense; 2023.
7. National Institute for Health and Care Excellence. Bipolar disorder: assessment and management. Clinical guideline CG185. National Institute for Health and Care Excellence; 2014, updated 2025.
8. Singh B et al. Bipolar disorder. The Lancet. 406(10506), 2025: 963-978.
9. McIntyre RS et al. Bipolar disorders. The Lancet. 396(10265), 2020: 1841-1856.
10. McIntyre RS et al. The clinical characterization of the adult patient with bipolar disorder aimed at personalization of management. World Psychiatry. 21(3), 2022: 364-387.
11. O’Connell KS et al. Genomics yields biological and phenotypic insights into bipolar disorder. Nature. 639, 2025: 968-975.
12. Mullins N et al. Genome-wide association study of more than 40,000 bipolar disorder cases provides new insights into the underlying biology. Nature Genetics. 53(6), 2021: 817-829.
13. Ching CRK et al. What we learn about bipolar disorder from large-scale neuroimaging: findings and future directions from the ENIGMA Bipolar Disorder Working Group. Human Brain Mapping. 43(1), 2022: 56-82.
14. Miura T et al. Comparative efficacy and tolerability of pharmacological treatments in the maintenance treatment of bipolar disorder: a systematic review and network meta-analysis. The Lancet Psychiatry. 1(5), 2014: 351-359.
15. Carvalho AF et al. Bipolar disorder. New England Journal of Medicine. 383(1), 2020: 58-66.